Europe
The company is expected to face growing competition from Abbott and Boston Scientific in heart implants, an analyst said.
Pharma and biotech stakeholders applauded the vote as Amsterdam achieved the hightest rate of acceptance of the EMA staff for relocatation, according to a survey.
Researchers are making great headway against cancer, even though it’s currently still the second-leading cause of death in the U.S.
The majority of the cuts will be in Germany and about 1,800 will be in the U.S.
Peptidream has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics.
Genentech scored two approvals from the FDA this week.
The company will focus on its biggest divisions: aviation, power and healthcare.
Loxo Oncology struck a deal with Bayer to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55B.
Novartis is not resting on the laurels of having the first-ever-approval for a CAR-T cancer drug, Kymriah.
PRESS RELEASES